Standout Papers

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diab... 2017 2026 2020 2023 469
  1. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial (2017)
    Christopher Sorli, Shin‐ichi Harashima et al. The Lancet Diabetes & Endocrinology

Immediate Impact

3 from Science/Nature 96 standout
Sub-graph 1 of 21

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
1 intermediate paper

Works of Jeffrey Unger being referenced

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
2017 Standout

Author Peers

Author Last Decade Papers Cites
Jeffrey Unger 711 363 194 14 817
Wayne H.-H. Sheu 608 235 218 13 830
Gretchen R. Esche 612 233 83 10 853
Charlotte Hindsberger 470 228 239 22 976
Kristina Johnsson 727 363 326 21 889
Aodán Tynan 633 146 86 8 892
Norm Rosenthal 616 362 283 19 769
Anne Sclater 326 154 217 14 650
Duncan J. Campbell 380 336 110 16 942
Francis Chun Chung Chow 644 291 183 16 833
Rodrigo M. Lago 382 260 176 13 753

All Works

Loading papers...

Rankless by CCL
2026